Company news
Resverlogix Corp. news in 2024
Resverlogix Corp.'s news releases, calls and decks from 2024, newest first.
Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024
September 3, 2024
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
July 31, 2024
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
July 16, 2024
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
May 28, 2024
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
May 13, 2024
Resverlogix Announces Change to Its Board of Directors
February 20, 2024
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
January 11, 2024